The global Lewy body dementia market size is expected to be worth USD 1.35 Billion in 2025. It can surge to a valuation of USD 2.27 Billion by 2032. The market is anticipated to exhibit a CAGR of 7.7% during the forecast period (2025-2032).
Government initiatives created for the awareness of Lewy body dementia (LBD) and investments made for dementia care centers can drive the market growth. The effort made by pharmaceutical companies to develop biomarkers and other tests for accurate diagnosis can further contribute to the market growth.
However, the lack of symptomatic treatment that permanently stalls the progression of Lewy body dementia can impede the market growth.
Key Market Insights
The Lewy body dementia market is expected to scale owing to the rising cases of progressive dementia and the use of biomarkers for effective diagnosis.
The full report is now available for purchase: https://www.coherentmi.com/industry-reports/lewy-body-dementia-market
Lewy Body Dementia Market Report Coverage
|
Report Coverage |
Details |
|
Market Revenue in 2025 |
USD 1.35 Billion |
|
Estimated Value by 2032 |
USD 2.27 Billion |
|
Growth Rate |
7.7% |
|
Historical Data |
2020–2024 |
|
Forecast Period |
2025–2032 |
|
Forecast Units |
Value (USD Billion) |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
|
|
Geographies Covered |
North America (U.S. and Canada), Latin America (Brazil, Argentina, Mexico, and Rest of Latin America), Europe (Italy, Spain, U.K., Germany, France, Russia, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific), Middle East (GCC Countries, Israel, and Rest of Middle East), and Africa (South Africa, North Africa, and Central Africa) |
|
Growth Drivers |
|
|
Opportunities |
|
|
Trends |
|
|
Restraints & Challenges |
|
Market Dynamics
The demand for definitive diagnostics to detect Lewy body dementia can drive the market growth. LBD covers Parkinson’s and dementia with Lewy bodies. The large rate of misdiagnosis despite having access to patient medical history, neurological examinations, and imaging tests is enabling the driver. The potential of novel diagnostic tests for the detection of alpha-synuclein can bode well for the market. For instance, the Syn-One Test by CND Lifesciences can accurately detect phosphorylated alpha-synuclein (P-SYN). The skin-based biopsy allows doctors to differentiate between disorders with similar symptoms.
Partnerships formed for funding clinical studies of dementia can shape the market growth. These partnerships aim to fuel the development of disease-modifying drugs for Lewy body dementia and other forms of dementia. The Accelerating Medicines Partnership in Parkinson’s Disease and Related Disorders (AMP PDRD), a public-private partnership established on July 17, 2024, is one such instance. It is expected to work in tandem with resources from various esteemed organizations and heavy capital to advance research and improve patient outcomes.
Market Opportunity: Biomarkers for Early Detection of LBD
Blood biomarkers can allow for the early diagnosis of LBD and enable targeted therapies. The detection of acetyl-L-carnitine (LAC) and free carnitine levels can allow clinicians to detect the disorder accurately. The research was published in Molecular Psychiatry on January 07, 2025, which identified the low levels of LAC caused dementia in men, while women had dementia with declining levels of LAC and free carnitine. This breakthrough can lead the way for a blood test that accurately monitors these compounds for the detection of early dementia in men and women.
Market Challenge: Complex Symptom Management of LBD
The management of LBD requires a team of specialists, which can be expensive for the average patient. It is challenging owing to motor impairment and cognitive dysfunction, a combination of pharmacological therapies and personalized care.
Analyst’s View
Recent Developments
IGC Pharma announced an upgrade to its AI platform, Multimodal Interpretable Transformer for Alzheimer’s (MINT-AD), for the early detection of dementia and Alzheimer’s, and dementia with Lewy bodies (DLB) on March 04, 2025. The platform is trained on clinical data from the Alzheimer's Disease Neuroimaging Initiative (ADNI), the National Alzheimer's Coordinating Center (NACC), and others.
Competitor Insights
Market Segmentation
Regional Insights
Related Reports :